| Price | 225.00p on 21-01-2026 at 19:35:12 |
|---|---|
| Change | 0.00p 0% |
| Buy | 227.00p |
| Sell | 225.00p |
| Last Trade: | Sell 8,799.00 at 225.00p |
| Day's Volume: | 88,505 |
| Last Close: | 225.00p |
| Open: | 226.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 223.00p - 228.00p |
| 52wk Range: | 187.50p - 292.00p |
| Market Capitalisation: | £1.93b |
| VWAP: | 225.66198p |
| Shares in Issue: | 859.52m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 8,799 | 225.00p | Uncrossing Trade |
16:35:13 - 21-Jan-26 |
| Sell* | 311 | 225.00p | Automatic Execution |
16:29:23 - 21-Jan-26 |
| Buy* | 30 | 226.314p | Suspected BUY Trade |
16:18:14 - 21-Jan-26 |
| Sell* | 7 | 225.00p | SI Trade |
16:17:09 - 21-Jan-26 |
| Buy* | 321 | 225.006p | Ordinary |
16:16:57 - 21-Jan-26 |
| Unknown* | 5,000 | 225.00p | Automatic Execution |
16:12:30 - 21-Jan-26 |
| Unknown* | 5,000 | 225.00p | Automatic Execution |
16:12:11 - 21-Jan-26 |
| Unknown* | 5,000 | 225.00p | Automatic Execution |
16:12:01 - 21-Jan-26 |
| Unknown* | 5,000 | 225.00p | Automatic Execution |
16:11:46 - 21-Jan-26 |
| Unknown* | 5,000 | 225.00p | Automatic Execution |
16:11:34 - 21-Jan-26 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 14th Jan 2026 7:00 am | RNS-R | Publication of Phase III Results in The Lancet |
| 7th Jan 2026 7:00 am | RNS-R | Positive Topline Results of Phase III Trial |
| 5th Jan 2026 7:00 am | RNS-R | Surufatinib + Camrelizumab PDAC Phase 3 initiation |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 29th Dec 2025 8:30 am | RNS | Blocklisting Six Monthly Return |
| 29th Dec 2025 8:30 am | RNS-R | NDA Acceptance in China for Fanregratinib |
| 29th Dec 2025 8:30 am | RNS-R | NDA Acceptance in China for Fanregratinib |
